FXR agonists INT ‐787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet‐induced ob/ob mouse model of NASH
Liver International · 2024
DOI: 10.1111/liv.15767 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2024. Verfasst von Laura G Di Pasqua und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: University of Pavia and by Intercept Pharmaceuticals, Inc..
Abstract (Originalsprache)
Background and Aims We have previously shown in a model of hepatic ischaemia/reperfusion injury that the farnesoid X receptor (FXR) agonist obeticholic acid (OCA) restores reversion‐inducing‐cysteine‐rich protein with Kazal motifs (RECK), an inverse modulator of metalloproteases (MMPs) and inhibitor of the sheddases ADAM10 and ADAM17 involved in inflammation and fibrogenesis. Here, the effects of FXR agonists OCA and INT‐787 on hepatic levels of RECK, MMPs, ADAM10 and ADAM17 were compared in a diet‐induced ob/ob mouse model of non‐alcoholic steatohepatitis (NASH).
Methods
Lep ob/ob NASH mice fed a high‐fat diet (HFD) or control diet (CD) for 9 weeks (wks) were treated with OCA or INT‐787 0.05% dosed via HFD admixture (30 mg/kg/day) or HFD for further 12 wks. Serum alanine transaminase (ALT) and inflammatory cytokines, liver RECK, MMP‐2 and MMP‐9 activity as well as ADAM10, ADAM17, collagen deposition (Sirius red), hepatic stellate cell activation (α‐SMA) and pCK + reactive biliary cells were quantified.
Results
Only INT‐787 significantly reduced serum ALT, IL‐1β and TGF‐β. A downregulation of RECK expression and protein levels observed in HFD groups (at 9 and 21 wks) was counteracted by both OCA and INT‐787. HFD induced a significant increase in liver MMP‐2 and MMP‐9; OCA administration reduced both MMP‐2 and MMP‐9 while INT‐787 markedly reduced MMP‐2 expression. OCA and INT‐787 reduced both ADAM10 and ADAM17 expression and number of pCK + cells. INT‐787 was superior to OCA in decreasing collagen deposition and α‐SMA levels.
Conclusion
INT‐787 is superior to OCA in controlling specific cell types and clinically relevant anti‐inflammatory and antifibrotic molecular mechanisms in NASH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
- Internal Medicine Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
- Institute of Molecular Genetics, Italian National Research Council (CNR), Pavia, Italy.
- Department of Biology and Biotechnology, University of Pavia, Pavia, Italy.
- Department of Medicine (DIMED), University of Padua, Padua, Italy.
- Department of Molecular Medicine (DMM), University of Padua, Padua, Italy.
ORCID-Profile: Giuseppina Palladini, Luca Fabris, Andrea Ferrigno, Mariapia Vairetti
Förderung
- University of Pavia and by Intercept Pharmaceuticals, Inc.
Zitieren
APA
Di Pasqua, L. G., Cagna, M., Palladini, G., Croce, A. C., Cadamuro, M., Fabris, L., Perlini, S., Adorini, L., Ferrigno, A., & Vairetti, M. (2024). FXR agonists INT ‐787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet‐induced ob/ob mouse model of NASH. Liver International. https://doi.org/10.1111/liv.15767
Vancouver
Di Pasqua LG, Cagna M, Palladini G, Croce AC, Cadamuro M, Fabris L, et al. FXR agonists INT ‐787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet‐induced ob/ob mouse model of NASH. Liver International. 2024. doi:10.1111/liv.15767
BibTeX
@article{DiPasqua2024,
author = {Di Pasqua, Laura G and Cagna, Marta and Palladini, Giuseppina and Croce, Anna C and Cadamuro, Massimiliano and Fabris, Luca and Perlini, Stefano and Adorini, Luciano and Ferrigno, Andrea and Vairetti, Mariapia},
title = {FXR agonists INT ‐787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet‐induced ob/ob mouse model of NASH},
journal = {Liver International},
year = {2024},
doi = {10.1111/liv.15767}
}
EUVIMED